Company registration number 03900712 (England and Wales)
RAD NEURIM PHARMACEUTICALS EEC LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
RAD NEURIM PHARMACEUTICALS EEC LIMITED
COMPANY INFORMATION
Directors
Professor N Zisapel
Y Zisapel
Secretary
Y Langer
Company number
03900712
Registered office
5th Floor Thames Tower
Station Road
Reading
Berkshire
RG1 1LX
Accountants
Myers Clark
Egale 1
80 St Albans Road
Watford
Hertfordshire
WD17 1DL
RAD NEURIM PHARMACEUTICALS EEC LIMITED
CONTENTS
Page
Directors' report
1
Accountants' report
2
Balance sheet
3
Notes to the financial statements
4
RAD NEURIM PHARMACEUTICALS EEC LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023
- 1 -

The directors present their annual report and financial statements for the year ended 31 December 2023.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Professor N Zisapel
Y Zisapel
Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
Professor N Zisapel
Director
16 September 2024
RAD NEURIM PHARMACEUTICALS EEC LIMITED
CHARTERED ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF RAD NEURIM PHARMACEUTICALS EEC LIMITED FOR THE YEAR ENDED 31 DECEMBER 2023
- 2 -
In accordance with the engagement letter dated 11 October 2007, and in order to assist you to fulfil your duties under the Companies Act 2006, we have compiled the financial statements of Rad Neurim Pharmaceuticals EEC Limited for the year ended 31 December 2023, set out on pages 3 and 4 from the accounting records and information and explanations you have given to us.

This report is made solely to the board of directors of Rad Neurim Pharmaceuticals EEC Limited, as a body, in accordance with the terms of our engagement letter dated 11 October 2007. Our work has been undertaken solely to prepare for your approval the financial statements of Rad Neurim Pharmaceuticals EEC Limited and state those matters that we have agreed to state to the board of directors of Rad Neurim Pharmaceuticals EEC Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Rad Neurim Pharmaceuticals EEC Limited and its board of directors as a body, for our work or for this report.

It is your duty to ensure that Rad Neurim Pharmaceuticals EEC Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and result of Rad Neurim Pharmaceuticals EEC Limited. You consider that Rad Neurim Pharmaceuticals EEC Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Rad Neurim Pharmaceuticals EEC Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Myers Clark
16 September 2024
Chartered Accountants
Egale 1
80 St Albans Road
Watford
Hertfordshire
WD17 1DL
RAD NEURIM PHARMACEUTICALS EEC LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2023
31 December 2023
- 3 -
2023
2022
Notes
£
£
£
£
Current assets
Cash at bank and in hand
2
2
Net current assets
2
2
Capital and reserves
Called up share capital
2
2
2

For the financial year ended 31 December 2023 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 16 September 2024 and are signed on its behalf by:
Professor N Zisapel
Director
Company registration number 03900712 (England and Wales)
RAD NEURIM PHARMACEUTICALS EEC LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
- 4 -
1
Accounting policies
Company information

Rad Neurim Pharmaceuticals EEC Limited is a private company limited by shares incorporated in England and Wales. The registered office is 5th Floor Thames Tower, Station Road, Reading, Berkshire, RG1 1LX.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Profit and loss account

The company has not traded during the year or the preceding financial period. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

1.3
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments' of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price.

Basic financial liabilities

Basic financial liabilities are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

1.4
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2
Called up share capital
2023
2022
2023
2022
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary Shares of £1 each
2
2
2
2
2023-12-312023-01-01trueCCH SoftwareCCH Accounts Production 2024.200No description of principal activityProfessor N ZisapelY ZisapelY Langerfalsefalse039007122023-01-012023-12-3103900712bus:Director12023-01-012023-12-3103900712bus:Director22023-01-012023-12-3103900712bus:CompanySecretary12023-01-012023-12-3103900712bus:RegisteredOffice2023-01-012023-12-31039007122023-12-31039007122022-12-3103900712core:ShareCapital2023-12-3103900712core:ShareCapital2022-12-3103900712bus:EntityHasNeverTraded2023-01-012023-12-3103900712bus:PrivateLimitedCompanyLtd2023-01-012023-12-3103900712bus:FRS1022023-01-012023-12-3103900712bus:AuditExemptWithAccountantsReport2023-01-012023-12-3103900712bus:FullAccounts2023-01-012023-12-31xbrli:purexbrli:sharesiso4217:GBP